GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 7,400.00
-500.00 (-6.33%)
At close: Mar 23, 2026
GC Genome Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 31,534 | 25,888 | 27,292 | 24,114 | 18,498 |
Other Revenue | - | - | - | - | -0 |
| 31,534 | 25,888 | 27,292 | 24,114 | 18,498 | |
Revenue Growth (YoY) | 21.81% | -5.15% | 13.18% | 30.36% | 36.46% |
Cost of Revenue | 16,905 | 14,181 | 13,595 | 13,349 | 11,318 |
Gross Profit | 14,628 | 11,707 | 13,697 | 10,765 | 7,180 |
Selling, General & Admin | 6,412 | 6,464 | 5,791 | 5,564 | 4,204 |
Research & Development | 6,478 | 6,053 | 7,355 | 8,121 | 4,841 |
Amortization of Goodwill & Intangibles | 40.45 | 37.75 | 35.12 | 36.26 | 29.1 |
Other Operating Expenses | 46.87 | 54.31 | 46.41 | 47.85 | 17.65 |
Operating Expenses | 13,393 | 12,940 | 13,537 | 14,000 | 9,289 |
Operating Income | 1,236 | -1,234 | 160.08 | -3,236 | -2,109 |
Interest Expense | -197.12 | -959.77 | -920.67 | -1,695 | -1,482 |
Interest & Investment Income | 1,218 | 1,059 | 482.41 | 508.99 | 297 |
Earnings From Equity Investments | 553.47 | - | - | - | - |
Currency Exchange Gain (Loss) | 191.24 | 882.39 | -83.19 | -160.36 | -12.42 |
Other Non Operating Income (Expenses) | -541.36 | 248.44 | -454.79 | 756.59 | 3,727 |
EBT Excluding Unusual Items | 2,460 | -3.2 | -816.17 | -3,826 | 420.4 |
Gain (Loss) on Sale of Investments | 1,828 | - | - | -2.93 | - |
Gain (Loss) on Sale of Assets | -139.05 | 1.37 | 1.57 | -44.89 | -13.83 |
Asset Writedown | - | -1,125 | - | - | - |
Pretax Income | 4,149 | -1,127 | -814.6 | -3,874 | 406.57 |
Income Tax Expense | 104.56 | 129.84 | -264.5 | -110.52 | 113.37 |
Net Income | 4,044 | -1,257 | -550.1 | -3,763 | 293.2 |
Net Income to Common | 4,044 | -1,257 | -550.1 | -3,763 | 293.2 |
Shares Outstanding (Basic) | 22 | 18 | 18 | 16 | 16 |
Shares Outstanding (Diluted) | 22 | 18 | 18 | 16 | 16 |
Shares Change (YoY) | 20.01% | -0.66% | 13.53% | 0.97% | -10.25% |
EPS (Basic) | 185.00 | -69.00 | -30.00 | -233.00 | 18.33 |
EPS (Diluted) | 185.00 | -69.00 | -30.00 | -233.00 | 18.33 |
Free Cash Flow | 985.56 | 49.4 | -4,065 | -5,639 | -2,935 |
Free Cash Flow Per Share | 45.08 | 2.71 | -221.71 | -349.17 | -183.51 |
Gross Margin | 46.39% | 45.22% | 50.19% | 44.64% | 38.81% |
Operating Margin | 3.92% | -4.76% | 0.59% | -13.42% | -11.40% |
Profit Margin | 12.83% | -4.86% | -2.02% | -15.61% | 1.58% |
Free Cash Flow Margin | 3.13% | 0.19% | -14.90% | -23.39% | -15.87% |
EBITDA | 4,103 | 1,986 | 3,701 | -429 | -51.89 |
EBITDA Margin | 13.01% | 7.67% | 13.56% | -1.78% | -0.28% |
D&A For EBITDA | 2,867 | 3,219 | 3,541 | 2,807 | 2,057 |
EBIT | 1,236 | -1,234 | 160.08 | -3,236 | -2,109 |
EBIT Margin | 3.92% | -4.76% | 0.59% | -13.42% | -11.40% |
Effective Tax Rate | 2.52% | - | - | - | 27.88% |
Advertising Expenses | 148.54 | 90.12 | 143.22 | 148.84 | 97.65 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.